Fig. 4: The genetic landscape and radiographic tumor response analysis. | Nature Communications

Fig. 4: The genetic landscape and radiographic tumor response analysis.

From: Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial

Fig. 4

Alterations as assessed by next-generation sequencing of baseline primary tumor samples (n = 47) (a). Comparisons of radiographic tumor response between HPV-positive (n = 9) and HPV-negative (n = 39) patients (P = 0.012) (b); TP53-mutant (n = 37) and TP53-wild-type (n = 10) patients (P = 0.006) (c); and TERT-mutant (n = 11) and TERT-wild-type (n = 36) patients by using the two-sided Mann–Whitney U nonparametric test (P = 0.01) (d). Correlation between HPV status (HPV-positive: n = 9; HPV-negative: n = 39) and TP53 (n = 37, P < 0.0001) or TERT mutations (n = 11, P = 0.16) by using the two-sided Mann–Whitney U nonparametric test (e). Comparisons of radiographic tumor response between TP53-mutant (n = 35) and TP53-wild-type (n = 3) patients (P = 0.807) (f); and TERT-mutant (n = 11) and TERT-wild-type (n = 27) patients (P = 0.049) (g) in HPV-negative patients by using the two-sided Mann–Whitney U nonparametric test. The histogram plots show the mean values of radiographic tumor response and standard deviation (SD). The dot represents an individual data point. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns no significance. Source data are provided as a Source Data file.

Back to article page